What is Oragenics's earnings per share (EPS)?

Oragenics (OGEN) reported diluted earnings per share of $-4.56 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oragenics Financials

OGEN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Oragenics (OGEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Oragenics passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.94x

For every $1 of reported earnings, Oragenics generates $0.94 in operating cash flow (-$9.2M OCF vs -$9.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-11.9x

Oragenics earns $-11.9 in operating income for every $1 of interest expense (-$9.4M vs $786K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$9.8M

YoY+6.9%

Oragenics reported -$9.8M in net income in fiscal year 2025. This represents an increase of 6.9% from the prior year.

EPS (Diluted)

$-4.56

Oragenics earned $-4.56 per diluted share (EPS) in fiscal year 2025. This represents an increase of 90.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4.4M

YoY+408.7%

5Y CAGR-24.2%

10Y CAGR-1.4%

Oragenics held $4.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Oragenics had 4M shares outstanding in fiscal year 2025. This represents an increase of 919.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-118.8%

5Y CAGR+38.1pp

10Y CAGR+128.7pp

Oragenics's ROE was -118.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$2.4M

YoY-41.8%

5Y CAGR-35.9%

10Y CAGR-12.1%

Oragenics invested $2.4M in research and development in fiscal year 2025. This represents a decrease of 41.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

OGEN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$38K-71.4%	$132K+51.2%	$87K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.4M-41.8%	$4.1M-73.4%	$15.5M+53.8%	$10.1M-4.9%	$10.6M-52.1%	$22.1M
SG&A Expenses	$7.0M+8.2%	$6.4M+18.2%	$5.5M+21.7%	$4.5M-15.0%	$5.3M+16.3%	$4.5M
Operating Income	-$9.4M+11.3%	-$10.6M+49.5%	-$20.9M-45.0%	-$14.4M+8.6%	-$15.8M+40.8%	-$26.6M
Interest Expense	$786K+2534.9%	$30K-2.5%	$31K+102.5%	$15K-4.1%	$16K+47.5%	$11K
Income Tax	-$137K	N/A	N/A	N/A	N/A	N/A
Net Income	-$9.8M+6.9%	-$10.6M+48.8%	-$20.7M-44.6%	-$14.3M+9.1%	-$15.7M+40.6%	-$26.4M
EPS (Diluted)	$-4.56	$-47.88	$-9.18-29.1%	$-7.11	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$931K+107.0%	$450K+31.7%	$342K	N/A	$879K-3.1%	$907K+36.7%	$663K
SG&A Expenses	N/A	$2.2M+73.4%	$1.3M-24.9%	$1.7M	N/A	$1.6M+11.4%	$1.4M-22.1%	$1.8M
Operating Income	N/A	-$3.1M-82.2%	-$1.7M+15.4%	-$2.0M	N/A	-$2.4M-5.7%	-$2.3M+6.3%	-$2.5M
Interest Expense	N/A	$7K-98.8%	$572K+187.4%	$199K	N/A	$10K+453.0%	$2K-74.6%	$7K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$3.1M-35.0%	-$2.3M-2.5%	-$2.2M	N/A	-$2.5M-6.8%	-$2.3M+5.9%	-$2.5M
EPS (Diluted)	N/A	$-1.96+36.8%	$-3.10	$-0.12	N/A	$-11.32+25.9%	$-15.27-2081.4%	$-0.70

OGEN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$10.1M+583.7%	$1.5M-70.4%	$5.0M-66.3%	$14.8M-47.7%	$28.2M+51.1%	$18.7M
Current Assets	$10.1M+583.7%	$1.5M-61.9%	$3.9M-72.9%	$14.3M-48.4%	$27.7M+54.1%	$18.0M
Cash & Equivalents	$4.4M+408.7%	$865K-75.2%	$3.5M-69.5%	$11.4M-58.1%	$27.3M+54.6%	$17.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M+6.1%	$1.7M-6.3%	$1.8M+2.8%	$1.7M+0.2%	$1.7M-5.0%	$1.8M
Current Liabilities	N/A	N/A	$1.8M+12.6%	$1.6M+10.4%	$1.4M+7.7%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.3M+4008.4%	-$212K-106.7%	$3.2M-75.6%	$13.0M-50.9%	$26.5M+57.2%	$16.8M
Retained Earnings	-$226.6M-4.5%	-$216.8M-5.1%	-$206.2M-11.1%	-$185.6M-8.3%	-$171.3M-10.9%	-$154.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$10.1M-20.8%	$12.7M+493.8%	$2.1M-44.7%	$3.9M+162.8%	$1.5M-71.7%	$5.2M+92.1%	$2.7M-23.3%	$3.5M
Current Assets	$10.1M-20.8%	$12.7M+493.8%	$2.1M-44.7%	$3.9M+162.8%	$1.5M-64.2%	$4.1M+154.1%	$1.6M-33.7%	$2.4M
Cash & Equivalents	$4.4M-61.4%	$11.4M+477.8%	$2.0M-42.3%	$3.4M+295.6%	$865K-72.5%	$3.1M+133.1%	$1.3M-34.9%	$2.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M-37.8%	$2.9M-32.7%	$4.3M+14.4%	$3.7M+121.5%	$1.7M-20.8%	$2.1M+53.7%	$1.4M+52.2%	$909K
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.3M-15.8%	$9.8M+562.1%	-$2.1M-1645.3%	$138K+165.0%	-$212K-106.9%	$3.1M+132.0%	$1.3M-49.5%	$2.6M
Retained Earnings	-$226.6M-1.0%	-$224.3M-1.4%	-$221.3M-1.0%	-$219.0M-1.0%	-$216.8M-1.6%	-$213.4M-1.2%	-$211.0M-1.1%	-$208.7M

OGEN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$9.2M-7.5%	-$8.6M-17.9%	-$7.3M+52.1%	-$15.2M-13.1%	-$13.5M+20.5%	-$17.0M
Capital Expenditures	N/A	N/A	N/A	$128K+190.6%	$44K	N/A
Free Cash Flow	N/A	N/A	N/A	-$15.4M-13.6%	-$13.5M	N/A
Investing Cash Flow	N/A	N/A	-$936K-710.5%	-$116K-163.3%	-$44K	N/A
Financing Cash Flow	$16.8M+180.7%	$6.0M+2006.1%	$284K+157.4%	-$495K-102.1%	$23.1M+41.8%	$16.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$2.8M+5.0%	-$3.0M-127.1%	-$1.3M+37.8%	-$2.1M-4.6%	-$2.0M-2.4%	-$2.0M-27.6%	-$1.5M+49.6%	-$3.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$169K-101.4%	$12.4M+9436.8%	-$133K-102.8%	$4.7M+1889.6%	-$261K-106.9%	$3.8M+358.6%	$821K-50.3%	$1.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OGEN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-55519.9%-44555.3pp	-10964.6%+7165.7pp	-18130.3%	N/A
Net Margin	N/A	N/A	-54858.1%-43994.2pp	-10864.0%+7198.1pp	-18062.0%	N/A
Return on Equity	-118.8%	N/A	-652.0%-542.1pp	-109.8%-50.5pp	-59.3%+97.6pp	-156.9%
Return on Assets	-97.8%+619.9pp	-717.7%-301.8pp	-415.9%-319.1pp	-96.8%-41.2pp	-55.6%+85.8pp	-141.5%
Current Ratio	N/A	N/A	2.15-6.8	8.95-10.2	19.17+5.8	13.40
Debt-to-Equity	0.22+8.2	-7.95-8.5	0.57+0.4	0.13+0.1	0.07-0.0	0.11
FCF Margin	N/A	N/A	N/A	-11675.7%+3860.1pp	-15535.8%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-31.2%	N/A	-1610.2%	N/A	-80.0%+93.8pp	-173.8%-80.4pp	-93.4%
Return on Assets	N/A	-24.1%+82.0pp	-106.2%-48.9pp	-57.3%	N/A	-47.3%+37.7pp	-85.1%-15.7pp	-69.3%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.22-0.1	0.29+2.3	-2.01-29.1	27.10+35.1	-7.95-8.6	0.69-0.4	1.04+0.7	0.35
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Xenetic Biosciences Inc XBIO

$6.1M

GRI Bio GRI

$3.3M

Aptevo Therapeutics Inc APVO

$4.0M

Onconetix ONCO

$1.1M

Quoin Pharmaceuticals Ltd QNRX

$10.1M

Frequently Asked Questions

Is Oragenics profitable?

No, Oragenics (OGEN) reported a net income of -$9.8M in fiscal year 2025.

What is Oragenics's return on equity (ROE)?

Oragenics (OGEN) has a return on equity of -118.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Oragenics's operating cash flow?

Oragenics (OGEN) generated -$9.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Oragenics's total assets?

Oragenics (OGEN) had $10.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Oragenics spend on research and development?

Oragenics (OGEN) invested $2.4M in research and development during fiscal year 2025.

How many shares does Oragenics have outstanding?

Oragenics (OGEN) had 4M shares outstanding as of fiscal year 2025.

What is Oragenics's debt-to-equity ratio?

Oragenics (OGEN) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Oragenics's return on assets (ROA)?

Oragenics (OGEN) had a return on assets of -97.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Oragenics's cash runway?

Based on fiscal year 2025 data, Oragenics (OGEN) had $4.4M in cash against an annual operating cash burn of $9.2M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Oragenics's Piotroski F-Score?

Oragenics (OGEN) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Oragenics's earnings high quality?

Oragenics (OGEN) has an earnings quality ratio of 0.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Oragenics cover its interest payments?

Oragenics (OGEN) has an interest coverage ratio of -11.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.